Literature DB >> 1720316

Detection of cerebrospinal fluid antibodies against myelin basic protein in patients with AIDS dementia complex.

C M Mastroianni1, G M Liuzzi, V Vullo, E Jirillo, S Delia, P Riccio.   

Abstract

We evaluated cerebrospinal fluid (CSF) antibody levels against a lipid-free, denatured form of myelin basic protein (LF-MBP) in 11 patients with AIDS dementia complex (ADC) by using an enzyme-linked immunosorbent assay (ELISA). In 9 out of 11 patients, anti-LF-MBP antibody levels were significantly higher than those observed both in 15 human immunodeficiency virus (HIV)-infected patients without neurological disorders and in 9 anti-HIV-negative subjects affected by other neurological diseases. Furthermore, we followed up anti-MBP levels in 5 out of the 11 ADC patients and detected a strict relationship with the encephalopathy progression. At the same time, with the aim to detect early demyelinating events we investigated CSF antibody levels against a lipid-bound, native-like form of MBP (LB-MBP). Results did not show any significant difference between LF-MBP and LB-MBP in terms of antibody reactivity. The detection of anti-MBP antibodies in CSF may provide the opportunity to assess a diagnostic tool for discovering demyelinating lesions in ADC patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1720316     DOI: 10.1007/bf03159938

Source DB:  PubMed          Journal:  Mol Chem Neuropathol        ISSN: 1044-7393


  2 in total

1.  Cerebrospinal fluid antiganglioside antibodies in patients with AIDS.

Authors:  M Sorice; T Griggi; A Circella; G Nicodemo; M Ciardi; C M Mastroianni; L Lenti; F Sorice
Journal:  Infection       Date:  1995 Sep-Oct       Impact factor: 3.553

2.  Antibodies to myelin oligodendrocyte glycoprotein in HIV-1 associated neurocognitive disorder: a cross-sectional cohort study.

Authors:  Peter Lackner; Bettina Kuenz; Markus Reindl; Maria Morandell; Thomas Berger; Erich Schmutzhard; Christian Eggers
Journal:  J Neuroinflammation       Date:  2010-11-17       Impact factor: 8.322

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.